PRESS RELEASE published on 04/15/2024 at 14:01, 2 years 6 months ago Original-Research: Apontis Pharma AG (von Montega AG): Kaufen Montega AG stuft Apontis Pharma AG hoch und aktualisiert das Kursziel auf 16,50 EUR aufgrund neuer Vertriebsstrategie und Kooperation mit Novartis. Analyst Tim Kruse empfiehlt Kauf Montega AG APONTIS PHARMA AG Kursziel 16,50 EUR Vertriebsstrategie Kooperation Novartis
BRIEF published on 04/05/2024 at 10:22, 2 years 7 months ago APONTIS PHARMA Secures Five-Year Distribution and Marketing Deal with Novartis for Asthma Medications Pharmaceutical Industry Financial Forecast APONTIS PHARMA Asthma Medications Novartis
BRIEF published on 04/05/2024 at 10:22, 2 years 7 months ago APONTIS PHARMA conclut un accord de distribution et de commercialisation de cinq ans avec Novartis pour des médicaments contre l'asthme Prévisions Financières Industrie Pharmaceutique PHARMA APONTIS Médicaments Contre L'asthme Novartis
PRESS RELEASE published on 04/05/2024 at 10:17, 2 years 7 months ago APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast APONTIS PHARMA partners with Novartis for asthma medications distribution and marketing, raising forecast for 2024 financial year Distribution Agreement APONTIS PHARMA Asthma Medications Novartis Forecast Increase
BRIEF published on 04/05/2024 at 10:15, 2 years 7 months ago APONTIS PHARMA AG Enhances Forecast Following Agreement with Novartis APONTIS PHARMA AG Financial Growth Forecast Upgrade Novartis Agreement Asthma Medications
BRIEF published on 04/05/2024 at 10:15, 2 years 7 months ago APONTIS PHARMA AG améliore ses prévisions suite à un accord avec Novartis Croissance Financière APONTIS PHARMA AG Mise À Niveau Des Prévisions Accord Novartis Médicaments Contre L'asthme
PRESS RELEASE published on 04/05/2024 at 10:10, 2 years 7 months ago EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications APONTIS PHARMA AG raises forecast following agreement with Novartis for asthma medications Forecast Raise Financial Outlook APONTIS PHARMA AG Novartis Agreement Asthma Medications
BRIEF published on 03/28/2024 at 07:35, 2 years 7 months ago APONTIS PHARMA Anticipates Profitable Growth in 2024 After Restructuring APONTIS PHARMA Single Pill Combinations Financial Results 2023 Profitable Growth 2024 Restructuring Program
BRIEF published on 03/28/2024 at 07:35, 2 years 7 months ago APONTIS PHARMA prévoit une croissance rentable en 2024 après sa restructuration Résultats Financiers 2023 PHARMA APONTIS Croissance Rentable 2024 Combinaisons De Pilules Uniques Programme De Restructuration
PRESS RELEASE published on 03/28/2024 at 07:30, 2 years 7 months ago APONTIS PHARMA expects profitable growth again in 2024 APONTIS PHARMA expects profitable growth in 2024 with sales forecasted to rise to EUR 41.7 million and positive EBITDA of EUR 1.8 million. Performance and efficiency improvements drive future growth EBITDA Profitable Growth APONTIS PHARMA Sales Forecast Efficiency Improvements
Published on 11/10/2026 at 14:45, 3 hours 28 minutes ago An Investigational Drug to Tackle Measles Outbreaks
Published on 11/10/2026 at 14:31, 3 hours 42 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 3 hours 43 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:30, 3 hours 43 minutes ago ACCESS Newswire Reports Third Quarter 2026 Results
Published on 11/10/2026 at 14:00, 4 hours 13 minutes ago Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
Published on 11/10/2026 at 18:02, 11 minutes ago Symrise AG announces Chief Financial Officer transition and extension of Walter Ribeiro’s Executive Board appointment
Published on 11/10/2026 at 18:00, 13 minutes ago 2CRSi SA: UET et 2CRSi s’associent pour apporter à l’Edge une puissance de calcul IA validée, sous garantie et refroidie par immersion
Published on 11/10/2026 at 18:00, 13 minutes ago 2CRSi SA: UET and 2CRSi Partner to Bring Validated, Warranty-Backed, Immersion-Cooled AI Compute to the Edge
Published on 11/10/2026 at 17:45, 28 minutes ago EQS-Adhoc: Airbus reports share buybacks for week starting 2 November 2026
Published on 11/10/2026 at 18:00, 13 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 28 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 38 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 41 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
